Marinomed Biotech Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Marinomed Biotech.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 20.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2024 | 7 | -7 | -5 | -5 | N/A |
| 12/31/2023 | 9 | -7 | -5 | -5 | N/A |
| 9/30/2023 | 11 | -6 | -6 | -6 | N/A |
| 6/30/2023 | 12 | -6 | -5 | -5 | N/A |
| 3/31/2023 | 12 | -7 | -5 | -5 | N/A |
| 12/31/2022 | 11 | -6 | -5 | -5 | N/A |
| 9/30/2022 | 13 | -5 | -5 | -4 | N/A |
| 6/30/2022 | 13 | -5 | -2 | -2 | N/A |
| 3/31/2022 | 12 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 12 | -6 | -6 | -5 | N/A |
| 9/30/2021 | 9 | -8 | -11 | -7 | N/A |
| 6/30/2021 | 9 | -7 | -12 | -9 | N/A |
| 3/31/2021 | 9 | -7 | -13 | -9 | N/A |
| 12/31/2020 | 8 | -6 | -11 | -7 | N/A |
| 9/30/2020 | 8 | -6 | -8 | -6 | N/A |
| 6/30/2020 | 7 | -6 | -9 | -5 | N/A |
| 3/31/2020 | 7 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 7 | -7 | -10 | -8 | N/A |
| 9/30/2019 | 5 | -14 | -8 | -8 | N/A |
| 6/30/2019 | 5 | -15 | -9 | -9 | N/A |
| 3/31/2019 | 5 | -14 | -7 | -7 | N/A |
| 12/31/2018 | 5 | -12 | -5 | -4 | N/A |
| 9/30/2018 | 6 | -4 | -4 | -4 | N/A |
| 12/31/2017 | 5 | -2 | N/A | -2 | N/A |
| 12/31/2016 | 4 | -2 | N/A | -3 | N/A |
| 12/31/2015 | 3 | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 93Z's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 93Z's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 93Z's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 93Z's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 93Z's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 93Z's Return on Equity is forecast to be high in 3 years time